TRANSPARENCY COUNCIL MEETING NO. 35/2023 SEPTEMBER 4, 2023
1. Strensiq (asfotasum alfa) CONDITIONAL Indication: under the drug program "Treatment of bone symptoms in the course of pediatric hypophosphatasia (HPP) (ICD-10 E83.3) with asfotasum alfa" Decision problem: preparation of a position paper on the evaluation of the drug
2. Tysabri (natalizumab) solution for injection CONDITIONAL Indication: under drug program B.29. "Treatment of patients with multiple sclerosis (ICD-10: G35)" Decision-making problem: preparing a position paper on the evaluation of the drug
3. phesgo (trastuzumab + pertuzumab) CONDITIONAL Indication: under drug program B.9.FM. "Treatment of patients with breast cancer (ICD-10: C50)". Decision-making problem: preparation of a position on the evaluation of the drug
4. Nilemdo (bempedoic acid) Indication: atherosclerosis Decision-making problem: preparation of a position on the appropriateness of granting reimbursement approval for a medicinal product
5. "Support of infertility treatment by in vitro fertilization - in vitro for residents of the Oświęcim district in 2024-2026". Decision-making problem: preparation of an opinion on the draft health policy program of local government units
TRANSPA... To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].Content locked
